• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Y-mAbs Therapeutics Inc.

    8/15/25 4:28:04 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $YMAB alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Y-mAbs Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value

    (Title of Class of Securities)


    984241109

    (CUSIP Number)


    08/08/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    984241109


    1Names of Reporting Persons

    Glazer Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,654,700.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,654,700.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,654,700.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.84 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP No.
    984241109


    1Names of Reporting Persons

    Paul J. Glazer
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,654,700.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,654,700.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,654,700.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.84 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Y-mAbs Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    202 CARNEGIE CENTER, SUITE 301, PRINCETON, NJ, 08540
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Glazer Capital, LLC, a Delaware limited liability company ("Glazer Capital"), with respect to the shares of Common Stock (as defined in Item 2(d)) held by certain funds and managed accounts to which Glazer Capital serves as investment manager (collectively, the "Glazer Funds"); and (ii) Mr. Paul J. Glazer ("Mr. Glazer"), who serves as the Managing Member of Glazer Capital, with respect to the shares of Common Stock held by the Glazer Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock (as defined in Item 2(d)) reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the business office of each of the Reporting Persons is 250 West 55th Street, Suite 30A, New York, New York 10019.
    (c)Citizenship:

    Glazer Capital is a Delaware limited liability company. Mr. Glazer is a United States citizen.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value
    (e)CUSIP No.:

    984241109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2,654,700
    (b)Percent of class:

    5.84%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    2,654,700

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    2,654,700

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Glazer Capital, LLC
     
    Signature:Paul J. Glazer
    Name/Title:Paul J. Glazer, Managing Member
    Date:08/15/2025
     
    Paul J. Glazer
     
    Signature:Paul J. Glazer
    Name/Title:Paul J. Glazer
    Date:08/15/2025
    Get the next $YMAB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $YMAB

    DatePrice TargetRatingAnalyst
    4/22/2025$3.00Neutral → Underperform
    BofA Securities
    11/18/2024$23.00Outperform
    Oppenheimer
    8/16/2024$20.00Overweight
    Cantor Fitzgerald
    6/28/2024$21.00Buy
    Truist
    5/10/2023$5.00 → $13.00Neutral → Outperform
    Wedbush
    4/3/2023Buy → Neutral
    Guggenheim
    1/27/2023$4.00Equal-Weight → Underweight
    Morgan Stanley
    1/5/2023Outperform → Market Perform
    Cowen
    More analyst ratings

    $YMAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tyagi Ashu was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)

    4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

    7/2/25 4:20:24 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hamill Laura was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)

    4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

    7/2/25 4:20:27 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wedell-Wedellsborg Johan was granted 25,080 shares, increasing direct ownership by 431% to 30,905 units (SEC Form 4)

    4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

    7/2/25 4:20:21 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wg Biotech Aps bought $44,232 worth of shares (6,455 units at $6.85), increasing direct ownership by 0.14% to 4,559,233 units (SEC Form 4)

    4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

    12/12/23 8:27:16 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedell-Wedellsborg Johan bought $44,232 worth of shares (6,455 units at $6.85) (SEC Form 4)

    4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

    12/12/23 8:26:25 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wg Biotech Aps bought $40,190 worth of shares (6,183 units at $6.50) and bought $850,222 worth of shares (121,366 units at $7.01), increasing direct ownership by 3% to 4,552,778 units (SEC Form 4)

    4 - Y-mAbs Therapeutics, Inc. (0001722964) (Issuer)

    12/11/23 5:25:50 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

    Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company's guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire Y-mAbs in $412.0 million transaction; transaction expected to close by the fourth quarter of 2025, subject to completion of tender offer and other customary conditionsAs of June 30, 2025, cash and cash equivalents were $62.3 millionIn light of the pending transaction, Y-mAbs will not be holding a webcast and conference call to discuss its second quarter 2025 results PRINCETON, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commer

    8/8/25 6:35:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

    PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will report results for the second quarter 2025 before the market open on Friday, August 8, 2025. In light of the previously announced transaction with affiliated entities of SERB Pharmaceuticals, Y-mAbs will not be hosting an earnings conference call. About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and

    8/7/25 7:30:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics

    Acquisition to Include Naxitamab-gqgk DANYELZA® (Naxitamab-gqgk), Further Broadening SERB's Rare Oncology Product Portfolio Transaction Expands SERB's Investment in the U.S. SERB to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Y-mAbs for $8.60 Per Share Represents 105% Premium to Y-mAbs Closing Share Price on August 4, 2025 WEST CONSHOHOCKEN, Pa. and PRINCETON, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals ("SERB"), a global specialty pharmaceutical company focused on medicines for rare diseases and medical emergencies, and Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) ("Y-mAbs" or "the Company"), a commercial-stage biopharmaceutical company focused on

    8/5/25 8:30:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Y-mAbs Therapeutics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Y-mAbs Therapeutics from Neutral to Underperform and set a new price target of $3.00

    4/22/25 7:23:34 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Y-mAbs Therapeutics with a new price target

    Oppenheimer initiated coverage of Y-mAbs Therapeutics with a rating of Outperform and set a new price target of $23.00

    11/18/24 8:23:54 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Y-mAbs Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Y-mAbs Therapeutics with a rating of Overweight and set a new price target of $20.00

    8/16/24 7:40:36 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    SEC Filings

    View All

    SEC Form SC 14D9 filed by Y-mAbs Therapeutics Inc.

    SC 14D9 - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

    8/18/25 9:24:22 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Y-mAbs Therapeutics Inc.

    SCHEDULE 13G - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

    8/15/25 4:28:04 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Y-mAbs Therapeutics Inc.

    SCHEDULE 13G - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

    8/12/25 4:16:22 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for DANYELZA issued to Y-MABS THERAPEUTICS INC

    Submission status for Y-MABS THERAPEUTICS INC's drug DANYELZA (SUPPL-8) with active ingredient NAXITAMAB-GQGK has changed to 'Approval' on 03/20/2024. Application Category: BLA, Application Number: 761171, Application Classification:

    3/21/24 10:20:07 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    Leadership Updates

    Live Leadership Updates

    View All

    Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

    NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit. "I am pleased to welcome Doug to Y-mAbs as the new DANYELZA Business Unit head," said Michael Rossi, President and Chief Executive Officer. "We believe Doug's extensive experience leading pharmaceutical commercialization and operations on a global scale will be instrumental in our co

    1/10/25 7:35:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

    NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer. "Y-mAbs is at a critical inflection point as we continue to gain U.S. commercial traction with DANYELZA® while simultaneously advancing the development of our differentiated Self-Assembly DisAssembly Pre

    7/1/24 4:05:00 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

    NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Norman LaFrance, M.D. as Chief Development Officer. "We are thrilled to welcome Dr. LaFrance to Y-mAbs," Mike Rossi, President and Chief Executive Officer. "Norman has an impressive track record in the research, development and commercialization of radiotherapeutics, molecular imaging, diagnostic and therapeutic products. With his deep expertise in develop

    6/5/24 7:05:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.

    SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

    11/14/24 4:32:10 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.

    SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

    11/12/24 6:00:40 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Y-mAbs Therapeutics Inc.

    SC 13G/A - Y-mAbs Therapeutics, Inc. (0001722964) (Subject)

    11/4/24 2:16:23 PM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $YMAB
    Financials

    Live finance-specific insights

    View All

    Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

    Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company's guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire Y-mAbs in $412.0 million transaction; transaction expected to close by the fourth quarter of 2025, subject to completion of tender offer and other customary conditionsAs of June 30, 2025, cash and cash equivalents were $62.3 millionIn light of the pending transaction, Y-mAbs will not be holding a webcast and conference call to discuss its second quarter 2025 results PRINCETON, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commer

    8/8/25 6:35:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

    PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will report results for the second quarter 2025 before the market open on Friday, August 8, 2025. In light of the previously announced transaction with affiliated entities of SERB Pharmaceuticals, Y-mAbs will not be hosting an earnings conference call. About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and

    8/7/25 7:30:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

    Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma updated to include naxitamab-gqgk (DANYELZA®)Dosed first patient in Phase 1 clinical trial evaluating CD38-SADA pretargeted radioimmunotherapy in patients with Relapsed/Refractory non-Hodgkin Lymphoma (Trial 1201)The Company to host virtual Radiopharmaceutical R&D update discussing Part A clinical data from its Phase I GD2-SADA clinical trial (Trial 1001) and announcing radioimmunotherapy and pipeline strategy on May 28, 2025As of March 31, 2025, cash and cash equiv

    5/13/25 6:35:00 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care